ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Neoadjuvant FOLFIRINOX in patients with locally advanced unresectable or borderline resectable pancreatic cancer

Neoadjuvant FOLFIRINOX in patients with locally advanced unresectable or borderline resectable pancreatic cancer
Authors, year Number of patients Regimen Radiographic response rate Number of patients with subsequent resection R0 resections Median survival for resected patients (months)
Conroy T, 2005 11 FOLFIRINOX 3 of 11 (27%) 0 0 –
Peddi PF, 2012 19 FOLFIRINOX then RT (n = 4) 6 of 18* (33%) 8 of 23 (35%) Not reported Not reported
Vasile E, 2012 15 FOLFIRINOX then CRT (n = 3) 6 of 15 (40%) 5 (33%) – 30.1 (all 15 patients)
Mahaseth H, 2013 24 FOLFIRINOX then CRT (n = 14) Not stated 6 (25%) Not reported Not reported
Hosein PJ, 2013 18 FOLFIRINOX then CRT (n = 10) Not stated 6 after CT, 3 after CRT (50%) 8 of 9 (89%) Not reported
Boone BA, 2013 13 FOLFIRINOX then SBRT (n = 5) Not stated 2 (15%) 1 of 2 (50%) Not reported
Christians KK, 2014 18 FOLFIRINOX then CRT Not stated 12 (67%) 12 of 12 (100%) 7 of 12 alive at median 22 months after diagnosis
Marthey L, 2015 77 FOLFIRINOX then RT (n = 24) 22 of 77 (28%) 28 (36%) 25 of 28 (89%) 24.9
Ferrone CR, 2015 40 FOLFIRINOX then CRT (n = 24) 36 of 40 (90%) 40 (100%) 37 (92%) Approximately 32
Blazer M, 2015 43 FOLFIRINOX then CRT (n = 23) 9 of 40 (23%)Δ 22 (51%) 19 (86%) 34.0
Mellon EA, 2015◊ 159 FOLFIRINOX (n = 23), GTX (n = 94), Gem (n = 28), or Gem/Abrax (n = 8), then SBRT Not stated 61 (38%) 59 (96%) 34.2
Sadot E, 2015 101 FOLFIRINOX then CRT (n = 63) (29%) 31 (31%) 16 of 31 (55%) Not yet reached(median follow-up 12 months)
Stein SM, 2016 31 FOLFIRINOX 5 of 29 (17%) 13 (42%) 13 of 13 (100%) Not reported
Kim SS, 2016 26 FOLFIRINOX then RT (n = 4) 13 of 26 (50%) 26 of 26 (100%) 24 of 26 (92%) Not yet reached (median follow-up 27.6 months)
Katz MH, 2016 22 FOLFIRINOX then CRT 6 of 22 (27%) 15 (68%) 14 of 15 (93%) Median 21.7
Murphy JE, 2018 48 FOLFIRINOX then short-course CRT (n = 27) or long-course CRT (n = 17) 19 of 48 (44%) 32 (65%) 31 of 32 (97%) Two-year overall survival 72%
FOLFIRINOX: short-term infusional fluorouracil plus leucovorin, irinotecan, and oxaliplatin; R0: microscopically complete; RT: radiation therapy; CRT: chemoradiotherapy; CT: computed tomography; SBRT: stereotactic body radiation therapy; GTX: gemcitabine plus docetaxel plus capecitabine; Gem: gemcitabine; Gem/Abrax: gemcitabine/nanoparticle albumin-bound placitaxel.
* The 19th patient did not have imaging available after three cycles of chemotherapy.
¶ These series include patients treated with FOLFIRINOX for both unresectable or borderline resectable locally advanced pancreatic carcinoma.
Δ Three patients died before restaging scans were completed.
◊ Data not reported separately for each neoadjuvant chemotherapy regimen. However, of the 49 patients with locally advanced pancreatic cancer, 5 responded sufficiently on imaging to undergo R0 resection after neoadjuvant therapy. All received FOLIRINOX.
Data from:
  1. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228.
  2. Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012; 13:497.
  3. Vasile E, De Lio N, Cappelli C, et al. Neoadjuvant modified FOLFOXIRI in locally advanced pancreatic cancer. Ann Oncol 2012; 23 Suppl 9:ix241. Abstr 726P.
  4. Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013; 42:1311.
  5. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12:199.
  6. Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013; 108:236.
  7. Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014; 19:266.
  8. Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma. Results of an AGEO multicentric prospective observational cohort. Ann Oncol 2015; 22:295.
  9. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261:12.
  10. Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 2015; 22:1153.
  11. Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 2015; 54:979.
  12. Sadot E, Doussot A, O'Reilly EM, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol 2015; 22:3512.
  13. Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016; 114:737.
  14. Kim SS, Nakakura EK, Wang ZJ, et al. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol 2016; 114:587
  15. Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 2016; 151:e161137.
  16. Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2018; 4:963.
Graphic 101296 Version 8.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟